**Assessing the Use of Quality Tolerance Limits in the Pharmaceutical Industry**

**PHUSE RBM Working Group – Quality Tolerance Limits Industry Survey 01Feb2022**

Steven Ponce ([Steven.Ponce@bms.com](mailto:Steven.Ponce@bms.com))

**Selected Figures**

Q = Question; T = Table

Contents

[Q3 2](#_Toc151404683)

[T1 (Q3) 2](#_Toc151404684)

[Q6 3](#_Toc151404685)

[Q6 (Alternative) 4](#_Toc151404686)

[Q23 5](#_Toc151404687)

# Q3

A graph of a number of different colored squares

Description automatically generated with medium confidence

# T1 (Q3)

**(Q3: Other category breakdown)**

*Table 1: placeholder*

Total Count = 13

|  |  |  |
| --- | --- | --- |
| Others: | Count | Percentage |
| Central Monitoring | 3 | 23.1% |
| Clinical Trial Supplies | 1 | 7.7% |
| Contracts | 1 | 7.7% |
| Diagnostics | 1 | 7.7% |
| IT developers | 1 | 7.7% |
| Imaging | 1 | 7.7% |
| Medical Monitoring | 1 | 7.7% |
| Medical Writing | 1 | 7.7% |
| Project Management | 1 | 7.7% |
| Risk Manager or RBQM lead | 1 | 7.7% |
| SaaS programmers | 1 | 7.7% |

# Q6

A chart of a diagram

Description automatically generated with medium confidence

# Q6 (Alternative)

A chart of different colored squares

Description automatically generated with medium confidence

# Q23

A close-up of a chart

Description automatically generated